Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom - 13/08/11
, Alejandro Arana, MD, MPH, FISPE b, Charles E. Wentworth, MS a, Carlos Fernández-Vidaurre, MD, MPH c, Raymond G. Schlienger, PhD, MPH d, Eulogio Conde, MD, PhD e, f
Reprint requests: Felix M. Arellano, Risk MR, LLC, 726 Route 202 South, Suites 320-361, Bridgewater, NJ 08807.Abstract |
Background |
Atopic dermatitis (AD) has been associated with an increased risk of lymphoma.
Objectives |
To assess the risk of lymphoma associated with AD and use of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) in a database allowing medical record validation.
Methods |
We conducted a nested-case control study using the United Kingdom–based The Health Improvement Network (THIN) database. We excluded patients with established risk factors for lymphoma. Cases of lymphoma were identified and classified after review of the medical records and hospital discharge files.
Results |
In the study population of 3,500,194 individuals, we identified 2738 cases of lymphoma (1722 non-Hodgkin lymphoma [NHL], 466 Hodgkin disease, 550 indeterminate cases; overall, 188 had cutaneous involvement) and 10,949 matched controls. AD was associated with an increased lymphoma risk (odds ratio [OR], 1.83; 95% CI, 1.41-2.36). In patients with AD referred to a dermatologist, the OR further increased (OR, 3.72; 95% CI, 1.40-9.87). We did not find any cases of lymphoma in TCI users; however, the number of patients exposed to TCI was insufficient to study any possible association between lymphoma and these drugs. TCS use was associated with an increased lymphoma risk (OR, 1.46; 95% CI, 1.33-1.61). The risk increase was dependent on TCS potency (OR for high-potency TCS, 1.80; 95% CI, 1.54-2.11). The increased risk involved both Hodgkin disease and NHL, especially NHL with skin involvement (OR for high-potency TCS, 26.24; 95% CI, 13.49-51.07).
Conclusion |
Our results show an association between lymphoma—especially skin lymphoma—and use of TCS. The risk increased with duration of exposure and potency of TCS.
Il testo completo di questo articolo è disponibile in PDF.Key words : Lymphoma, skin lymphoma, topical corticosteroids, atopic dermatitis, risk
Abbreviations used : AD, GP, HD, NHL, OR, TCI, TCS, THIN
Mappa
| Supported by an unrestricted grant from Novartis. Risk MR had contractually the final decision on content and destination of the manuscript, as well as where to submit it. |
|
| Disclosure of potential conflict of interest: F. M. Arellano receives grant support from Novartis, Schering-Plough, and Sepracor. A. Arana receives grant support from Novartis and Schering-Plough. C. E. Wentworth receives grant support from Novartis. C. Fernández-Vidaurre and R. Schlienger are employed by Novartis. The rest of the authors have declared that they have no conflict of interest. |
Vol 123 - N° 5
P. 1111 - Maggio 2009 Ritorno al numero
Articolo precedente
- Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy
- Gabriele Di Lorenzo, Pasquale Mansueto, Maria Luisa Pacor, Manfredi Rizzo, Francesco Castello, Nicola Martinelli, Vito Ditta, Claudia Lo Bianco, Maria Stefania Leto-Barone, Alberto D’Alcamo, Gaetana Di Fede, Giovam Battista Rini, Anne Marie Ditto
- UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo
- Regine Gläser, Fatemeh Navid, Winfried Schuller, Christian Jantschitsch, Jürgen Harder, Jens M. Schröder, Agatha Schwarz, Thomas Schwarz
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?